期刊文献+

MS-275体外诱导膀胱癌细胞凋亡的机制探讨 被引量:2

Explore on the mechanism of MS-275 inducing apoptosis in bladder cancer cell in vitro
暂未订购
导出
摘要 目的研究组蛋白去乙酰化酶(HDAC)抑制剂MS-275对膀胱癌T24细胞的诱导凋亡作用,并初步探讨其分子机制。方法用MTT法检测MS-275对T24细胞的生长抑制作用,并观察其有效作用浓度,采用荧光显微镜及原位末端标记(TUNEL)法观察和检测MS-275对T24细胞的诱导凋亡作用,采用流式细胞仪(FCM)检测Bcl-2和Bax在细胞内表达的动态变化。结果 MS-275抑制T24细胞的半抑制浓度(IC50)为(5.21±0.61)μmol/L。4.0μmol/L的MS-275处理T24细胞后可观察到典型的凋亡形态学变化,且随着作用时间的延长,细胞凋亡率逐渐升高,同时引起Bcl-2及Bax的表达率分别下调和上调。结论 HDAC抑制剂具有体外诱导膀胱癌细胞凋亡的作用,其作用机制涉及Bcl-2及Bax表达的动态改变。 Objective To investigate the apoptosis effect induced by MS-275, a histone deacetylase inhibitor, on bladder cancer T24 cell, and primarily discuss its molecular mechanism. Methods The cell growth inhibition was evaluated by MTT assay and the effective concentration was observed. The cell apoptosis was detected by fluorescence microscope and TUNEL mothed, respectively. The dynamic change of Bc1-2 and Bax expressing in T24 cell was measured by flow eytometry. Results The IC50 of MS-275 inhibiting the growth of T24 cell lines was (5.21±0.61) μmol/L. Typical apoptotic morphological change was observed in T24 cell treated by MS-275 at concentration of 4.0 μmol/L. Apoptotic rate were increased as time went on, with Bcl-2 down-regulated and Bax up-regulated. Conclusion HDAC inhibitor can induce apoptosis in bladder cancer cell in vitro and the change of expression of Bcl-2 and Bax is involved in its molecular mechanism.
出处 《中国医药导报》 CAS 2012年第28期33-34,39,共3页 China Medical Herald
基金 上海市科技发展基金项目(项目名称:膀胱肿瘤基因转录治疗的研究 项目编号03ZR14118)
关键词 膀胱癌 组蛋白去乙酰化酶 细胞凋亡 Bladder cancer Histone deacetylase Apoptosis
  • 相关文献

参考文献7

  • 1Ploeg M,Aben KH,Kiemeney LA. The present and future burden of urinary bladder cancer in the world [J]. World J Urol,2009,27:289- 293.
  • 2Nishioka C,Ikezoe T,Yang J,et al. Simuhaneous inhibition of DNA methyhransfe, rase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells[J].l,euk Res ,2011,35(7) :932-939.
  • 3Altmann A, Eisenhut M, Bauder WU ,et al. Therapy of thyroid carcinoma wilh the iistone deacetylase inhibitor MS-275 [J]. Eur J Nuci Med MolImaging,2010,37(12):2286-2297.
  • 4Adams JM,Cory S. The Bcl-2 apoptotic switch in cancer development and therapy [J]. Oncogene ,2007,26(9 ) : 1324-1337.
  • 5Cory S,Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch [J]. Cancer Cell, 2005,8 : 5-6.
  • 6Ha cker S,Karl S,Mader l,ct al. Histone deacetylasc inhibitors prime medulloblastoma cells h~r chemotherapy -induced apoptosis by enhancing p53-dependent Bax activation [J]. Oncogene, 2011,30( 19 ) : 2275-2281.
  • 7Jiang Y,Wang Y ,Su Z,e! al. Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA [J]. Mol Med Report,2010,3(4):613-619.

同被引文献30

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics [ J ]. 2012. CA Canc- er J Clin ,2012,62 : 10 - 29.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics [ J ]. CA Cancer J Clin ,2009,59:225 - 249.
  • 3Kosaka N, Ignchi H, Oehiya T. Circulating mieroRNA in body fluid:A new potential biomarker for cancer diagnosis and prognosis [ J ]. Cancer Sci,2010,101:2087 -2092.
  • 4Catto JW,Alcaras A,Bjartell AS,et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review [ J ]. Eur Urol, 2011,59 : 671 - 681.
  • 5Friel AM, Coreoran C, Crown J, et al. Relevance of circulating tumor cells, extracellular nueleic acids, and exosomes in breast cancer [ J ]. Breast Cancer Res Treat,2010,123:613 -625.
  • 6Kosaka N, Iguchi H, Ochiya T. Circulating mieroRNA in body fluid:A new potential biomarker for cancer diagnosis and prognosis [ J ]. Caneer Sei,2010,101:2087 -2092.
  • 7Schaefer A, Stephan C, Buseh J, et al. Diagnostic, prognostic and thera- peutic implications of mieroRNAs in urologic tumors[ J]. Nat Rev Urol.2010,7:286 - 297.
  • 8Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-me- diated gene silencing[ J] .Cell ,2008,132:9 - 14.
  • 9Wu W, Sun M, Zou GM, et al. MicroRNA and cancer: Current status and prospective [ J ]. Int J cancer,2007,120 ( 5 ) :953 - 960.
  • 10Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer[ J ]. Br J Sung,2007,94( 1 ) :23 - 30.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部